Prosecution Insights
Last updated: November 20, 2026

Timothy R Rozof, USPTO Patent Examiner

Listed by the USPTO as ROZOF, TIMOTHY R

Tech Center 1600 • Art Units: 1625

This examiner grants 73% of resolved cases

Analysis

ROZOF, TIMOTHY R has 983 resolved cases in Tech Center 1600 and Art Unit 1625. The allowance rate is 72.6%, and the interview lift is 23.4%, indicating that interviews are associated with improved allowance outcomes. The median time to allowance is 739 days, providing a relatively defined timing reference for prosecution planning.

The principal companies are Fujifilm Holdings Corporation, Janssen Pharmaceutica NV, and The Regents of the University of California. The leading firms are FOLEY HOAG, LLP (General), OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., and BakerHostetler. Practitioners may find interviews useful for resolving issues before further prosecution steps, while retaining a disciplined written record.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

72.6%
Allow Rate
+12.6% vs TC avg
1,032
Total Applications
+23.4%
Interview Lift
739
Avg Prosecution Days
Based on 983 resolved cases, 2023–2026

Rejection Statute Breakdown

2.5%
§101 Eligibility
32.8%
§102 Novelty
21.3%
§103 Obviousness
25.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18967488 BUPROPION AS A MODULATOR OF DRUG ACTIVITY Non-Final OA ANTECIP BIOVENTURES II LLC
18886532 ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18885092 COMPOUND AND LIPID COMPOSITION Non-Final OA FUJIFILM Corporation
18447057 METHOD AGAINST SNAKE ENVENOMATION Final Rejection National Tsing Hua University
18837956 METHODS OF TREATING PROSTATE CANCER Non-Final OA AstraZeneca AB
17926424 A COMPOSITION FOR IMPROVING QOL OF A 40-YEAR-OLD OR OLDER POSTMENOPAUSAL WOMAN WITHOUT MENOPAUSAL DISORDER Non-Final OA DAICEL CORPORATION
18266917 USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER Final Rejection Yale University
18976869 SUBSTITUTED HETEROCYCLIC COMPOUNDS Non-Final OA Bristol-Myers Squibb Company
18276762 BODY TEMPERATURE LOWERING AGENT, BODY TEMPERATURE ELEVATION SUPPRESSOR, FOOD COMPOSITION FOR LOWERING BODY TEMPERATURE,AND FOOD COMPOSITION FOR SUPPRESSING BODY TEMPERATURE ELEVATION Final Rejection University of Tsukuba
18639526 METHODS OF TREATING SWI/SNF DEREGULATED CANCERS Non-Final OA Fred Hutchinson Cancer Center
18768496 TREATMENT OF MIGRAINE Non-Final OA Allergan Pharmaceuticals International Limited

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Timothy R Rozof's allowance rate?

72.6% of resolved applications examined by Timothy R Rozof were allowed (983 resolved cases), compared with 51.3% across Art Unit 1625 over the last five years.

Does an interview help with examiner Timothy R Rozof?

This examiner's interview lift is +23.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Timothy R Rozof take to allow a patent?

Applications allowed by Timothy R Rozof took 739 days on average from filing to allowance.

Which art unit does examiner Timothy R Rozof work in?

Timothy R Rozof examines applications in Art Unit 1625 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month